The Pennsylvania Society of Oncology and Hematology represents more than 200 physicians and other health care professionals who care for cancer patients. The Society is a non-profit corporation devoted to the improvement of hematologic and oncologic care of patients.

Membership in the Society is open to physicians, allied health professionals, and institutions with a demonstrated interest and involvement in the care of patients with hematologic and oncologic disorders. It is also open to residents and fellows who are actively enrolled in a full-time residency program in hematology or oncology in Pennsylvania or who are in an appropriate fellowship program. Corporate entities involved in the care and treatment of cancer patients may also become members.

The site provides resources for cancer patients, including a searchable database of Society members for those individuals seeking an oncologist, hematologist, surgical oncologist, or radiation oncologist.

The Pennsylvania Society of Oncology and Hematology is grateful to our Corporate Sponsors, whose donations help us fulfill our mission.

ASCO Addresses New Policies That Threaten Access to Opioids

Marilyn J. Heine, MD, FACP was recently interviewed by ASCO for their recent article on new policies that threaten access to opioids. Dr. Heine commented that “Policymakers who seek to tackle the opioid epidemic should focus primarily on the main drivers of opioid use disorder – social and environmental factors and mental illness – as well as treatment for opioid use disorder. While judicious prescribing is important, patients with cancer and cancer survivors should not be subjected to arbitrary prescription limits. In 2013 and 2014, the National Survey on Drug Use and Health found that only 22.1% of people who misused prescription painkillers got them from a doctor”.   Read the full article


The Conquer Cancer Foundation (CCF) has established a Hurricane Relief Fund dedicated to people with cancer who have been devastated by hurricanes and are in need of critical support services. For additional information and to donate, click here: www.conquer.org/relieffund


CAP, ACCC, LUNGevity & CHEST partner on Process Improvement Toolkit for molecular testing programs for Non-Small Cell Lung Cancer (NSCLC).

Read more  (1.17MB pdf)

Approval of BAVENICO® Injection

EMD Serono and Pfizer announced the approval of BAVENCIO® (avelumab) Injection on March 23, 2017.

Learn More:
Approval Information (pdf)
Full Prescribing Information (pdf)                     

Questions regarding this approval should be directed to: Susan Sproat, CPA, CHONC, CMR
at Pfizer Oncology (

Our Corporate Members

Pennsylvania Society of Oncology and Hematology
777 East Park Drive, PO Box 8820
Harrisburg, PA 17105-8820
(717) 558-7750 phone
(717) 558-7841 fax

This website brought to you by:

Website design by Sister Webs Design Studio, where 5% of profits are donated to women's cancer funds

Our Corporate Members